On March 28, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), reported it will be announcing its 2017 Annual Results for the year ended December 31, 2017 at 7:00am CEST on Friday, April 13, 2018 (Press release, Kiadis, MAR 28, 2018, View Source [SID1234525133]). The Kiadis management will also be hosting an analyst and investor conference call at 2:00pm CEST / 8:00am EDT on Friday, April 13, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information, please contact:

Kiadis Pharma:
Karl Hård, Head of IR & Communications
Tel. +31 (0) 611 096 298
[email protected] Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0) 203 714 1787
[email protected]